Evidence map›Paper›PMID 39116276›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2024

Validation of Noninvasive Detection of Hyperkalemia by Artificial Intelligence-Enhanced Electrocardiography in High Acuity Settings.

David M Harmon, Kan Liu, Jennifer Dugan, Jacob C Jentzer, Zachi I Attia, Paul A Friedman, John J Dillon

Abstract readLetterValidation Study
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

David M HarmonDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-8102-3380
Kan LiuDepartment of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-5625-8180
Jennifer DuganDepartment of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1483-3201
Jacob C JentzerDepartment of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-6366-2859
Zachi I AttiaDepartment of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9706-7900
Paul A FriedmanDepartment of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota.
John J DillonDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-2873-1249

Funding

Mayo Clinic StARR ProgramR38HL150086 · NHLBI · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC, KARL A. NATH · 2020 to 2026
$2.5M
Mayo Clinic, National Institutes of Health John J. Dillon, NIH 5R38HL150086-02, NIH 5R38HL150086-02NHLBI NIH HHS R38 HL150086
6 · The paper itself

Abstract

Background: Artificial intelligence (AI) electrocardiogram (ECG) analysis can enable detection of hyperkalemia. In this validation, we assessed the algorithm's performance in two high acuity settings. Methods: An emergency department (ED) cohort (February to August 2021) and a mixed intensive care unit (ICU) cohort (August 2017 to February 2018) were identified and analyzed separately. For each group, pairs of laboratory-collected potassium and 12 lead ECGs obtained within 4 hours of each other were identified. The previously developed AI ECG algorithm was subsequently applied to leads 1 and 2 of the 12 lead ECGs to screen for hyperkalemia (potassium >6.0 mEq/L). Results: The ED cohort (N=40,128) had a mean age of 60 years, 48% were male, and 1% (N=351) had hyperkalemia. The area under the curve (AUC) of the AI-enhanced ECG (AI-ECG) to detect hyperkalemia was 0.88, with sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive likelihood ratio (LR+) of 80%, 80%, 3%, 99.8%, and 4.0, respectively, in the ED cohort. Low-eGFR (<30 ml/min) subanalysis yielded AUC, sensitivity, specificity, PPV, NPV, and LR+ of 0.83, 86%, 60%, 15%, 98%, and 2.2, respectively, in the ED cohort. The ICU cohort (N=2636) had a mean age of 65 years, 60% were male, and 3% (N=87) had hyperkalemia. The AUC for the AI-ECG was 0.88 and yielded sensitivity, specificity, PPV, NPV, and LR+ of 82%, 82%, 14%, 99%, and 4.6, respectively in the ICU cohort. Low-eGFR subanalysis yielded AUC, sensitivity, specificity, PPV, NPV, and LR+ of 0.85, 88%, 67%, 29%, 97%, and 2.7, respectively in the ICU cohort. Conclusions: The AI-ECG algorithm demonstrated a high NPV, suggesting that it is useful for ruling out hyperkalemia, but a low PPV, suggesting that it is insufficient for treating hyperkalemia.

Indexed as

Artificial IntelligenceElectrocardiographyHyperkalemiaAgedFemaleHumansMaleMiddle AgedPredictive Value of Tests

Identifiers

PMID39116276
PMCPMC11321728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.